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Enterococci are important nosocomial pathogens (1,2).
Their emergence in the past two decades is in many respects
attributable to their resistance to many commonly used
antimicrobial agents (aminoglycosides, aztreonam, cepha-
losporins, clindamycin, the semi-synthetic penicillins nafcillin
and oxacillin, and trimethoprim-sulfamethoxazole) (3). Expo-
sure to cephalosporins is a particularly important risk factor
for colonization and infection with enterococci (4-6). Thus, the
era in which safe and effective cephalosporins became widely
available has also been an era of enterococcal ascendance.
Ampicillin Resistance
Ampicillin is the therapy of choice for enterococcal
infections. Ampicillin MICs for Enterococcus faecalis, the
most commonly isolated enterococcal species from clinical
cultures, generally are 0.5 to 4.0 µg/mL, whereas for the less
commonly isolated E. faecium, MICs are 4 to 8 µg/mL.
E. faecalis and E. faecium account for >95% of enterococcal
isolates from clinical cultures. Low-level ampicillin resis-
tance in enterococci is attributable to the production of a low-
affinity penicillin-binding protein (PBP), PBP 5 (7). PBP 5s
have been identified in several enterococcal species. Those of
E. faecalis,  E. faecium, and the closely related E. hirae
demonstrate <75% nucleic acid identity, but the fact that
antibodies raised against one bind to all three suggests
substantial structural similarity (8).
Increased ampicillin resistance in enterococci is
attributable to either the production of beta-lactamase or
alterations in the expression or structure of PBP 5. Beta-
lactamase production has been described almost exclusively
in  E. faecalis and is attributable in most cases to the
acquisition of the Staphylococcus aureus beta-lactamase
operon (9-11). Beta-lactamase production occurs at a low level
in enterococci, conferring a minor increase in MIC at standard
inoculum. MIC increases more dramatically at high
inoculum, however, and animal studies suggest that
expression of this determinant may affect the outcome of
endocarditis (12).
Ampicillin resistance resulting from changes in PBP 5 is
primarily a clinical problem in E. faecium. The first detailed
information about PBP 5-mediated ampicillin resistance
arose from several lines of investigation. Williamson et al.
noted that penicillin resistance expressed by E. faecium was
related to the amount and the affinity of PBP 5 (13). The
observation that enterococci could grow normally in penicillin
concentrations enough to saturate all the PBPs, except PBP 5,
suggested that PBP 5 was capable of carrying out all the
functions necessary for cell-wall synthesis. Eliopoulos et al.
derived a hypersusceptible mutant of a clinical E. faecium
strain and noted that it no longer produced detectable
amounts of PBP 5 (14). Subsequent studies confirmed that the
lack of PBP 5 expression in this mutant was due to loss of the
pbp5 gene (15). Fontana et al. described in vitro mutants of
E. hirae 9790 that expressed increased levels of resistance to
ampicillin (MIC 64 µg/mL) (16). These mutants were found to
produce increased quantities of PBP 5. In the initially
analyzed strain, increased PBP 5 production was associated
with a deletion within an upstream open reading frame that
was characterized as a penicillin-binding protein synthesis
repressor (psr) (17). A more recent study suggests that psr
may serve as a global regulator of cell-wall synthesis genes in
enterococci (18).
E. faecium strains expressing very high levels of
ampicillin resistance (MIC >128 µg/mL) emerged in U.S.
medical centers in the late 1980s (19). Molecular analysis of
these strains suggested that the increase was attributable to
mutations within the pbp5 gene, which decreased the binding
affinity of PBP 5 for ampicillin (20,21). One clinical study
associated colonization with ampicillin-resistant E. faecium
and prior therapy with extended-spectrum cephalosporins
(22).
During the late 1980s, the prevalence of methicillin-
resistant staphylococci was also increasing in U.S. hospitals
(1), resulting in increased use of vancomycin. The discovery
that antibiotic-associated diarrhea and pseudomembranous
colitis were due to Clostridium difficile further fueled
vancomycin use (23).
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Vancomycin and ampicillin resistance in clinical Enterococcus faecium strains has developed in the
past decade. Failure to adhere to strict infection control to prevent the spread of these pathogens has been
well established. New data implicate the use of specific classes of antimicrobial agents in the spread of
vancomycin-resistant enterococci (VRE). Extended-spectrum cephalosporins and drugs with potent activity
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Figure. Comparison of arrangements of the VanA and VanB
glycopeptide resistance operons. Essential genes and those involved
in regulation of expression of the resistance determinant are marked.
Vancomycin Resistance
Vancomycin-resistant enterococci (VRE) were first
reported in 1986, nearly 30 years after vancomycin was
clinically  introduced. The primary inciting factor was likely
the use of orally administered vancomycin for treating
antibiotic-associated diarrhea in hospitals. Vancomycin
resistance is conferred by one of two functionally similar
operons, VanA or VanB (Figure) (24). The VanA and VanB
operons are highly sophisticated resistance determinants,
which suggests that they evolved in other species and were
acquired by enterococci. The difference in the guanine-
cytosine (G-C) content of the genes of the VanB operon
(roughly 50% G-C) (25) in comparison to typical enterococcal
genes (35% to 40% G-C) (3) is compelling evidence for this
acquisition. The conditions that would favor substantial
colonization by naturally glycopeptide-resistant species
(probably streptomycetes) and persistence of enterococci
include high vancomycin concentrations in the gastrointesti-
nal tract. Substantially high levels of glycopeptides in the
gastrointestinal tract are achievable by oral administration,
since these agents are not absorbed, resulting in fecal
vancomycin concentrations high enough to favor colonization
with vancomycin-resistant streptomycetes, but not high
enough to kill the notably tolerant enterococcus. Hence, it is
reasonable to presume that oral administration of
glycopeptides to humans was a major factor in the emergence
of vancomycin resistance in enterococci. The European VRE
outbreak’s apparent origin in animals (who were fed oral
glycopeptides as growth promoters) further supports this
scenario.
Risk Factors for Multidrug-Resistant Enterococci
More than 95% of VRE recovered in the United States are
E. faecium; virtually all are resistant to high levels of
ampicillin. The phenotypic association of ampicillin and
vancomycin resistance is in some instances due to genetic
linkage. We reported transferable ampicillin and VanB-type
vancomycin resistance from E. faecium strains isolated in
northeast Ohio (26). Both pbp5 and the vanB operon were
located in the chromosome and linked as a result of the
insertion of a VanB transposon (Tn5382) immediately
downstream of pbp5 (15). Both determinants were located
within a larger mobile element that was able to transfer
between E. faecium strains. This larger transposon is widely
disseminated; it is found in clonally unrelated E. faecium
isolates from New York, Pennsylvania, Florida, Missouri,
Ohio, and Hawaii (27).
E. faecium is less pathogenic than E. faecalis; in fact,
many VRE infections resolve without active antimicrobial-
drug therapy (28). However, in specific patient populations,
notably in liver transplant patients and patients with
hematologic malignancies, VRE cause serious and often fatal
disease (29,30). Therefore, it is well worth understanding the
factors that promote the emergence and spread of multidrug-
resistant VRE.
Frequently identified risk factors for VRE colonization
and infection include prolonged hospital stays, exposure to
intensive care units, transplants, hematologic malignancies,
and exposure to antibiotics (31). The epidemiology of VRE
spread in the hospital involves both person-to-person
transmission and selective antibiotic pressure. Very specific
practices designed to prevent the person-to-person spread of
VRE have been recommended by the Hospital Infection
Control Practices Advisory Committee to the Centers for
Disease Control and Prevention and are in place in many
hospitals (32). These measures include surveillance for
colonization, identification of colonized and infected patients,
isolation or cohorting of colonized persons, strict use of gloves
and gowns by people coming into contact with the patient,
thorough room cleaning after patient discharge, and efforts to
limit use of vancomycin in hospitals. In geographically
limited outbreaks caused by the dissemination of a single
VRE clone, these practices have successfully eliminated the
organisms from the hospital (33-35). In larger, more
disseminated outbreaks caused by several different VRE
clones, infection control measures and control of vancomycin
use have shown only limited efficacy, suggesting selection
pressure by antimicrobial drugs other than vancomycin
(36,37).
Antibiotics other than glycopeptides have been linked
with increased risk for colonization and infection with VRE,
most prominently, the extended-spectrum cephalosporins
and antibiotics with potent activity against anaerobic
bacteria (26,31,38,39). These associations have been noted in
retrospective, uncontrolled studies.
Nonglycopeptide Antibiotics and VRE
Are there compelling reasons to believe that cephalospor-
ins or antibiotics with potent activity against anaerobic
bacteria  increase risk for VRE? Early studies reported VRE
strains in which exposure to vancomycin increased the
susceptibility to beta-lactams (40). It was hypothesized that
PBP 5 was unable to process peptidoglycan precursors
terminating in D-lactate. Therefore, expression of vancomy-
cin resistance, whose mechanism in both VanA and VanB
strains involves the substitution of D-lactate for D-alanine at
the terminus of the pentapeptide precursors, would need to
involve other PBPs in cell-wall synthesis. These other PBPs
would be susceptible to beta-lactams, including cephalospor-
ins. However, mutants resistant to synergism are relatively
easy to select in vitro, and strains resistant to such synergism
are commonly found in the clinical setting (41).
The cephalosporin association may be related to the fact
that virtually all VRE in the United States express high-level
ampicillin resistance. The high-level ampicillin-resistant
strains express even higher degrees of resistance to extended-
spectrum cephalosporins (>10,000 µg/mL) (26). The concen-
trations of cephalosporins achievable in bile (as high as 5,000
µg/mL for ceftriaxone) (42-44) can inhibit or kill virtually all
upper gastrointestinal bacterial flora, except for VRE. On the185 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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Table 1. Pretreatment with antibiotics and vancomycin-resistant
enterococci (VRE) colonization after gastric administration of 102 CFU
vancomycin and ampicillin-resistant Enterococcus faecium C68 (46)
         Approximate log10 CFU VRE/g stool
Day 3 Day 6 Day 9 Day 13 Day 16
Saline   2   2.5 3 2.5 2.5
Piperacillin-   2   2 2 2 2
  tazobactam
Ticarcillin- >9 >9 8.2 6.8 6.8
  clavulanic acid
Ceftriaxone >9   8.8 8.4 7.2 6
Table 2. Antibiotic treatment and persistence of high-level colonization
with vancomycin and ampicillin-resistant Enterococcus faecium C68
(47)
       Approximate log10 CFU VRE/g stoola
Day 0 Day 4-5 Day 9-10 Day 14-15 Day 19-20
Saline   9.5   8.3   6   3.8   3.5
Vancomycin (SQ) >9 >9 >9 >9 >9
Vancomycin (oral) >9 >9 >9 >9 >9
Antibiotics with potent antianaerobic activity
Piperacillin- >9 >9 >9 >9 >9
  tazobactam
Ticarcillin- >9 >9 >9 >9 >9
  clavulanic acid
Clindamycin >9 >9 >9 >9 >9
Cefotetan >9 >9   8.8   7.8   8
Metronidazole >9 >9 >9 >9 >9
Ampicillin >9 >9   8   7.2   7
Ampicillin- >9 >9 >9   7.8   7.7
  sulbactam
Antibiotics with relatively poor activity against anaerobic bacteria
Cefepime >9 >9 6.2 5 4.8
Ceftriaxone >9   8.8 8.4 7.2 6
Aztreonam >9   9 4.3 4.2 3.8
Ciprofloxacin >9   8.8 6 5.2 5
aVRE = vancomycin-resistant enterococci; SQ = subcutaneous.
other hand, antienterococcal penicillins such as piperacillin,
which appear to be protective against VRE in some clinical
studies, achieve biliary concentrations in excess of
1,000 µg/mL in human bile after standard doses (45). These
concentrations exceed the MIC of most VRE for piperacillin
(256 to 1024 µg/mL). It is therefore within reason that the
potentially protective effect observed with piperacillin is
explainable by its direct inhibition of VRE in the upper
gastrointestinal tract.
We tested this hypothesis in an animal model in which
subcutaneous doses of different antimicrobial agents were
administered to mice for 2 days, followed by intragastric
injection of small numbers (ca. 100 CFU) of a highly
ampicillin-resistant VRE strain B E. faecium C68 (46). Stool
samples were subsequently collected over a 2- to 3-week
period to determine whether high-level VRE colonization was
established. In this model, subcutaneous administration of
piperacillin-tazobactam was found to protect against high-
level VRE colonization, whereas ceftriaxone and ticarcillin-
clavulanic acid (with antienterococcal activity equivalent to
the cephalosporins) promoted high-level VRE colonization
(Table 1). These results are consistent with a model in which
piperacillin is protective because of direct inhibition of VRE in
the upper gastrointestinal tract, whereas ceftriaxone and
ticarcillin promote colonization because they inhibit
everything but VRE, thereby permitting high-level coloniza-
tion.
A direct activity of antianaerobic antibiotics against VRE
is more difficult to understand, since some of these antibiotics
are among the most active antienterococcal agents
(ampicillin-sulbactam, piperacillin-tazobactam), and most of
the extended-spectrum cephalosporins have relatively weak
activity against anaerobes. Conceivably, however, these
antibiotics exhibit potent activity against species that
successfully compete with enterococci for colonization of the
gastrointestinal tract, thereby promoting persistence of high-
level VRE colonization once it is successfully established. We
tested this hypothesis in a separate animal model in which
high-level VRE colonization was established by intragastric
injection of 106 CFU of C68 after administration of oral
vancomycin (47). This technique established colonization of
mouse stool with 109 CFU of VRE in all animals. When oral
vancomycin was discontinued, colonization levels declined at
a regular and predictable rate; most animals had no
detectable colonization after 3 weeks. We tested the effects of
subcutaneous administration of different antibiotics on the
persistence of high-level VRE colonization (Table 2).
Vancomycin and antibiotics with potent activity against
anaerobic bacteria (ampicillin-sulbactam, cefoxitin,
clindamycin, metronidazole, piperacillin-tazobactam, and
ticarcillin-clavulanic acid) promoted persistence of high-level
VRE colonization, even though some had excellent activity
against enterococci and had been shown to prevent VRE
colonization in the other model (see above). In contrast,
antibiotics with relatively poor antianaerobic activity
(aztreonam, cefepime, ceftriaxone, ciprofloxacin) did not
promote high-level colonization.
Antibiotics and VRE Colonization and Infection
The above results suggest a model for antibiotic influence
on the spread of VRE. Commonly used antibiotics that
achieve high gastrointestinal concentrations but are inactive
against enterococci, such as the cephalosporins, ticarcillin,
and perhaps vancomycin, favor colonization with high levels
of VRE in the stool. Antibiotics active against anaerobic
bacteria, which are the primary competitors of enterococci for
colonizing the gastrointestinal tract, favor the persistence of
high levels of VRE in stool but may or may not (depending on
their intrinsic antienterococcal activity) favor colonization in
uncolonized patients. Antibiotics that meet both criteria, such
as ticarcillin-clavulanic acid, should be particularly
associated with VRE. In a citywide analysis of hospitals in the
greater Cleveland area, the use of ticarcillin-clavulanic acid
was associated with higher hospital rates of clinical VRE (26).
A positive, although not statistically significant, association
was noted for extended-spectrum cephalosporins, while a
negative but statistically insignificant association was noted
for the combination of ampicillin, ampicillin-sulbactam,
piperacillin, and piperacillin-tazobactam.
The frequent association of cephalosporins with VRE
colonization and the failure to associate piperacillin-
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driving force for the emergence and spread of these organisms
within institutions may be the predilection for establishing
new colonizations. This is not to say that antimicrobial agents
that promote persistence of high-level colonization will not be
important for promoting VRE outbreaks, but that this effect is
less pronounced if high-volume use of cephalosporins (or
ticarcillin-clavulanic acid) does not create receptive new
environments for establishing new colonization.
These data also suggest that refined strategies can be
developed to limit the emergence and spread of VRE within
hospitals. Commitment to serious infection control practices
and limitation of vancomycin use must remain the
cornerstones of any successful strategy. However, it is
possible to envision settings where surveillance-culturing
systems are taken seriously and patients who are colonized
with VRE are routinely identified. In such settings, the choice
of which empiric antibiotic to administer for a presumed
nosocomial infection would be affected by the colonization
status of the patient. In patients known to be colonized with
VRE, broad-spectrum agents that lack significant activity
against anaerobes (such as extended-spectrum cephalospor-
ins of fluoroquinolones) would be preferred, on the
assumption that potent anaerobic activity would not be
required for treating the infection. If the patient is not
colonized with VRE, administration of a potent
antienterococcal broad-spectrum agent such as piperacillin-
tazobactam may be preferred. In this manner, both the
establishment of new colonization and the level of
colonization of those already colonized could be minimized.
Conclusions
Multidrug-resistant enterococci continue to pose prob-
lems in U.S. medical centers. The best available evidence
suggests that the emergence and spread of these pathogens
are promoted by poor infection control techniques and by
antibiotic selective pressure. Antibiotic selective pressure
favoring the emergence and spread of VRE may involve more
than simply the extent of vancomycin use. Specifically,
extended-spectrum cephalosporins and similarly active beta-
lactams and drugs with potent activity against anaerobes
appear to predispose to VRE colonization and infection. On
one hand, data from animal models suggest that the
cephalosporins predispose to establishment of VRE coloniza-
tion through their potent activity against many bacteria and
essential lack of activity against ampicillin-resistant
enterococci. On the other hand, antianaerobic antibiotics
appear to favor persistence of high levels of VRE colonization
through their activity against competing flora. A more detailed
understanding of the impact of different antibiotics on the upper
and lower gastrointestinal flora will be an important step in
controlling the emergence and spread of VRE.
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